Tamoxifen Current Events | Tamoxifen News
|
|
|
Sort By:
Page Views | Date |
Potential dangers of long term tamoxifen use
Tamoxifen prolongs the life of women with breast cancer and may significantly reduce the risk of developing the disease in those with an inherited tendency. But, suggests a leading article in the Journal of Clinical Pathology, long term use may produce other serious abnormalities, including cancer. view more (1999-02-12)
Identifying the potential for tamoxifen resistance in patients
Tamoxifen is a widely used and highly successful drug in the treatment of breast cancer, though resistance to tamoxifen is still a concern in recurrent disease (affecting 25-35% of patients), since therapy resistant metastatic tumor cells are a major cause of death. view more (2009-06-11)
Further breakthroughs for breast cancer patients
Researchers at the Tenovus Centre for Cancer Research at Cardiff University have made a breakthrough in breast cancer treatment that could help save the lives of women who become resistant to breast cancer drugs such as tamoxifen. view more (2008-01-21)
Chemotherapy and tamoxifen reduce risk of second breast cancer
Among breast cancer patients, both chemotherapy and tamoxifen independently reduced the risk of developing a second cancer in the other breast, according to a study published online December 25 in the Journal of the National Cancer Institute. The risk reduction persisted for at least 10 and 5 years, respectively. view more (2007-12-26)
Long-term tamoxifen use increases risk of an aggressive, hard to treat type of second breast cancer
While long-term tamoxifen use among breast cancer survivors decreases their risk of developing the most common, less aggressive type of second breast cancer, such use is associated with a more than four-fold increased risk of a more aggressive, difficult-to-treat type of cancer in the breast opposite, or contralateral, to the initial tumor. view more (2009-08-26)
TAMOXIFEN FOR PREVENTION OF BREAST CANCER - ENCOURAGING RESULTS BUT RISKS STILL UNCLEAR (pp 813, 817)
Early findings from a randomised trial investigating the effectiveness of tamoxifen to prevent breast cancer are reported in this week’s issue of THE LANCET. Although tamoxifen reduced breast cancer incidence by a third compared with women given placebo, the authors of the study caution that it is still too early to fully assess the risk to... view more... (2002-09-11)
Early Promise Of Alternative Hormone Treatment For Breast Cancer
A fast-track study in this week's issue of THE LANCET suggests that the drug anastrozole could be an effective option for the treatment of postmenopausal women with hormone-sensitive early breast cancer. Tamoxifen therapy for five years after surgery is the established treatment for postmenopausal women with hormone-sensitive breast cancer.... view more... (2002-06-19)
Tamoxifen chemoprevention tied to early detection of breast cancer
The drug tamoxifen does not prevent or treat estrogen receptor (ER) negative breast cancer, but it can make the disease easier to find, researchers report in the Oct. 1 Journal of the National Cancer Institute. view more (2008-10-08)
Herbal Menopause Therapy a Good Fit for Breast Cancer Patients?
When it comes to understanding the effectiveness and safety of using herbal therapies with other drugs, much is unknown. Now, a University of Missouri researcher will study how black cohosh - an herbal supplement often used to relieve hot flashes in menopausal women - interacts with tamoxifen, a common drug used to treat breast cancer. view more (2008-10-08)
Ireland Cancer Center researcher finds standard treatment for breast cancer not followed
Research out of the Ireland Cancer Center of University Hospitals Case Medical Center, in collaboration with six integrated health plans that are part of the Cancer Research Network, found that the majority of older women with early stage breast cancer fail to adhere to the standard of treatment - five years of daily oral use of the... view more... (2007-12-26)
Gene variation affects tamoxifen's benefit for breast cancer
One of the most commonly prescribed drugs for breast cancer, tamoxifen, may not be as effective for women who inherit a common genetic variation, according to researchers at the University of Michigan and the Mayo Clinic. view more (2005-12-19)
New research shows no link between aromatase inhibitors and cardiovascular problems
New evidence has emerged that, contrary to some current fears, aromatase inhibitors (AIs) are not associated with an increased risk of heart problems in women who take them to prevent their breast cancer recurring. view more (2008-04-17)
Researchers Discover Method in Mice to Restore Tamoxifen Sensitivity in Resistant Breast Cancer
The widely used breast cancer drug tamoxifen (Nolvadex®), which can become less effective over time, might retain its full strength indefinitely if used along with a second drug, according to new research in mice conducted by investigators from the National Cancer Institute (NCI), part of the National Institutes of Health, and their partners. view more (2006-12-21)
First IBIS results show tamoxifen reduces breast cancer in healthy high-risk women
First results from the long-awaited IBIS trial into the use of tamoxifen to prevent breast cancer in healthy women at high risk have firmly established that the drug can indeed cut the incidence of the disease. These preliminary results were presented today (Wednesday 20 March) at the 3rd European Breast Cancer Conference in Barcelona together... view more... (2002-03-19)
Combining therapies can improve survival for early-stage breast cancer patients
Patients with early-stage breast cancer who are treated with both chemotherapy and tamoxifen have a higher survival rate than patients who receive only tamoxifen. view more (2007-04-04)
Radiotherapy Best Option After Surgery For Ductal Carcinoma In Situ (p 95)
UK research published in this week's issue of THE LANCET suggests that women with a pre-invasive cancer of the breast known as ductal carcinoma in situ (DCIS) are less likely to progress to invasive cancer if they are given radiotherapy after surgery. Mammographic breast screening (introduced in the UK National health Service in 1988) has led to... view more... (2003-07-09)
A new take on growth factor signaling in tamoxifen resistance
Differences in growth factor (GF) signaling may cause the poor prognosis in some breast cancer cases. A new study, published in the open access journal BMC Medical Genomics, suggests that some estrogen receptor-positive breast cancers respond poorly to tamoxifen because of increased GF signaling. view more (2009-06-24)
Breast cancer drug shows promise against serious infections
An FDA-approved drug used for preventing recurrence of breast cancer shows promise in fighting life-threatening fungal infections common in immune-compromised patients, such as infants born prematurely and patients with cancer. view more (2009-07-21)
'Arimidex' (anastrozole) significantly reduces the risk of contralateral breast tumours compared to gold-standard tamoxifen
Latest results from the ATAC (Arimidex, Tamoxifen Alone or in Combination) study in early breast cancer, presented today at the 3rd European Breast Cancer Conference (EBCC), show that treatment with 'Arimidex' more than halved the risk of post-menopausal women developing new tumours in the other previously healthy (contralateral) breast compared... view more... (2002-03-21)
Letrozole following tamoxifen may benefit women with breast cancer
Switching to the drug letrozole following 5 years of treatment with tamoxifen reduces the risk of hormone-dependent breast cancer recurrence, but not overall survival, among postmenopausal women. view more (2005-09-07)
|
|
|
|
Sort By:
Page Views | Date |
|
